JOJohn Charles O'HOro

John Charles O'HOro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John Charles O'HOro has a total of 547 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study – CORRIGENDUM

    by Dan Ilges, Dylan Kosaski, Maria Teresa Seville, Alyssa K. McGary, John C. O’hOro, Christine L. Snozek, Ryan W. Stevens, Aditya Shah


  • Open Access

    The Influence of the COVID-19 Pandemic on Influenza Vaccination Refusal and Patient Satisfaction

    by Olivia M Man, Jack W McHugh, Jeremy Young, Laurie L Wilshusen, Lacey Hart, Tripp Welch, John C O’hOro, Douglas W Challener

    Objective: To examine how the COVID-19 pandemic influenced seasonal influenza vaccination behaviors, healthcare engagement, and patient satisfaction. Methods: We retrospectively analyzed influenza vaccination records of adult primary care patients in Southwestern Minnesota during two 3-year phases: Pre-Pandemic (1/1/2017—2/28/2020) and Pandemic-Plus (3/1/2020—12/31/2023). Vaccination status was defined as “always vaccinated” (AV), “never vaccinated” (NV), or “intermittently vaccinated” (IV) for seasonal influenza. Standardized patient experience surveys were used to determine patient dissatisfaction. Results: In the Pandemic-Plus phase, 7.0% (n=3,556) of the Pre-Pandemic AV and 48.7% (n=16,710) of the Pre-pandemic IV never received another influenza vaccine. Compared to AV, IV and NV patients were more likely to reside in areas with greater socioeconomic deprivation [odds ratio (95% confidence interval): 1.58 (1.53-1.62); 1.99 (1.94—2.05), respectively], have a high school education or less [2.86 (2.74-2.98); 3.38 (3.23-3.53)], and report greater healthcare disengagement [1.59 (1.55-1.64); 4.21 (4.09-4.33)]. After adjusting for area deprivation index and medical comorbidities, the odds ratio of healthcare disengagement increased among the NV versus AV between phases [3.33 (3.24-3.41); 4.23 (4.10-4.35)]. In a multivariable subgroup analysis of patients who completed satisfaction surveys, those with severe health comorbidities were less likely AV [NV vs AV 1.21 (1.14-1.27)] and more likely to report healthcare dissatisfaction [NV vs AV 1.25 (1.18-1.33)]. Conclusions: The COVID-19 pandemic altered vaccination behaviors and healthcare satisfaction, especially among those at high risk of developing influenza-related complications. Medical providers and public health officials should be aware of factors associated with vaccine refusal to better target interventions.

  • Open Access

    Clinical characteristics associated with hospital-onset bacteremia and fungemia among cancer and transplant patients

    by Kalvin C. Yu, John C. O’hOro, ChinEn Ai, Molly Jung, Samantha Bastow

    Objective: This study quantified the burden of hospital-onset bacteremia and fungemia (HOB) among cancer and transplant patients compared to other patients.Methods: A retrospective cross-sectional study used data from 41 hospitals between October 2015 and June 2019. Hospitalizations were segmented into categories using diagnosis-related groups (DRG): myeloproliferative (MP) cancer, solid tumor cancer, transplant, and non-cancer/non-transplant (“reference group”). To quantify the association between DRG and HOB, multivariable adjusted Poisson regression models were fit. Analyses were stratified by length of stay (LOS).Results: Of 645,315 patients, 59% were female and the majority 41 years of age or older (76%). Hospitalizations with MP cancer and transplant demonstrated higher HOB burden compared to the reference group, regardless of LOS category. For all hospitalizations, the >30 days LOS category had a higher burden of HOB. The median time to reportable HOB was within 30 days regardless of duration of hospitalization (reference, 8 days; solid tumor cancer, 8 days; transplant, 12 days; MP cancer, 13 days).Conclusion: MP cancer and transplant patients had a higher burden of HOB compared to other hospitalized patients regardless of LOS. Whether these infections are preventable should be further evaluated to inform quality metrics involving reportable bacteremia and fungemia.


  • Open Access

    Beyond Words: Enhancing Clinical Guideline Comprehension With Icons

    by Isin Y Comba, John C O’hOro, Joel E Gordon, Yngve Falck-Ytter, Matthew M Moore, Rebecca L Morgan, Reem A Mustafa, Adarsh Bhimraj

    The GRADE (Grading Recommendations, Assessment, Development, and Evaluations) framework is widely applied in clinical guidelines to facilitate transparent evidence evaluation. While developing Infectious Diseases Society of America (IDSA) guidelines on the management of patients with COVID-19, panel members suggested developing and implementing a visual aid to enable quicker identification of key information by providers at bedside seeking guidance. We conducted a mixed-method study evaluating the usability of a newly designed infographic/icon using a survey and focus groups. The survey incorporated a simulated COVID-19 IDSA guideline with and without the icon, followed by comprehension questions. Focus group discussions provided qualitative feedback on the GRADE methodology and icon usability. The survey was returned by 289 healthcare providers. There was no statistical difference in the correct response rates between icon-aided and non-icon-aided guideline questions (McNemar’s Chi-squared test, p>0.1 for both questions). Interactions with the icon notably increased the time taken and number of clicks required to respond to the first question (Wilcoxon signed-rank test, pp=0.38). Most subjects (85%) indicated that the icon improved the readability of the guidelines. A focus group follow-up suggested alternative designs for the icon. The study highlights the promise of iconography in clinical guidelines, although the specific icons tested did not measurably improve usability metrics. Future research should focus on icon design and testing within a formal usability framework, considering the impact of GRADE language on user experience.

  • Open Access

    Leveraging real-time patient data during the COVID-19 pandemic

    by John C. O’hOro, Douglas W. Challener, Cory Kudrna, Jason R. Buckmeier, Steve G. Peters, Daryl J. Kor, Mark W. Matson, Andrew D. Badley, Charles D. Burger, Rajeev Chaudhry

  • Holding Our Breath—Looking for Treatments for Mild to Moderate COVID-19

    by John C. O’hOro

    Mild COVID-19 therapeutics with guideline support currently are limited to options for those who are at high risk of disease progression and have a lower

  • Open Access

    Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records

    by Christopher F. Bell, Daniel C. Gibbons, Myriam Drysdale, Helen J. Birch, Emily J. Lloyd, Vishal Patel, Corinne Carpenter, Katherine Carlson, Ediz S. Calay, Arjun Puranik, et al.

    Background: To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness of sotrovimab versus no treatment in preventing severe clinical outcomes. Methods: This observational retrospective cohort study analyzed Mayo Clinic electronic health records. Non-hospitalized adult patients diagnosed with COVID-19 from May 26, 2021 and April 23, 2022 and at high risk of COVID-19 progression were eligible. The primary outcome was 29-day all-cause hospitalization and/or death. Outcomes were described for patients treated with sotrovimab, other mAbs, or antivirals, and eligible but untreated patients, and compared between sotrovimab-treated and propensity score (PS)-matched untreated cohorts. Results: We included 35,485 patients (sotrovimab, 1369; other mAbs, 6488; antivirals, 133; high-risk untreated, 27,495). A low proportion of patients treated with sotrovimab (n = 33/1369, 2.4%), other mAbs (n = 147/6488, 2.3%), or antivirals (n = 2/133, 1.5%) experienced all-cause hospitalization or death. Among high-risk untreated patients, the percentage of all-cause hospitalization or death was 3.3% (n = 910/27,495). In the PS-matched analysis, 2.5% (n = 21/854) of sotrovimab-treated patients experienced all-cause hospitalization and/or death versus 2.8% (n = 48/1708) of untreated patients (difference, –0.4%; p = 0.66). Significantly fewer sotrovimab-treated patients required intensive care unit admission (0.5% vs 1.8%; difference, –1.3%; p = 0.002) or respiratory support (3.5% vs 8.7%; difference, –5.2%; p < 0.001). Conclusions: There was no significant difference in the proportion of sotrovimab-treated and PS-matched untreated patients experiencing 29-day all-cause hospitalization or mortality, although significantly fewer sotrovimab-treated patients required intensive care unit admission or respiratory support.


  • Open Access

    Echocardiographic Findings and Subsequent Risk of Native Valve Endocarditis

    by Juan Andres Quintero-Martinez, Joya-Rita Hindy, Hector R Villarraga, Brian D Lahr, Mark J Dayer, Martin H Thornhill, John C O'Horo, Hector I Michelena, Nandan S Anavekar, Parham Sendi, et al.

    Background: The association of echocardiographic findings and subsequent risk of left-sided native valve endocarditis (LS-NVE) is undefined. The aim of this study was to determine if transthoracic echocardiographic (TTE) measurements are associated with the subsequent development of LS-NVE in patients without cardiac predisposing conditions. Methods: Institutional databases were evaluated for adults diagnosed with LS-NVE from 2008 to 2020. Patients with prosthetic valves, cardiovascular implantable electronic devices, intracardiac devices, injection drug use, and predisposing cardiac conditions were excluded. Only patients who had a TTE performed 6 months to 3 years before the development of LS-NVE were included as cases. Controls were patients within the same Mayo location with a TTE report and were matched in a 1:3 ratio according to age, gender, Charlson Comorbidity Index, and echocardiography date. Results: There were 148 cases and 431 matched controls. As compared to controls, IE cases had a higher prevalence of diabetes mellitus (46.6% vs. 30.4%) and chronic kidney disease (46.6% vs. 28.1%) (p<0.001). Left ventricular outflow tract velocity (p=0.017), left ventricular ejection fraction (p=0.018), and E: e’ ratio (p=0.050) were associated with LS-NVE. Conclusions: Echocardiographic measurements were associated with subsequent LS-NVE development in this pilot study. A larger cohort of LS-NVE patients, however, is needed to validate these findings.

  • Open Access

    Bloodstream Infection Due to Coagulase-Negative Staphylococci: Impact of Species on Prevalence of Infective Endocarditis

    by Sara F. Haddad, Brian D. Lahr, Sebastian Santos Patarroyo, Supavit Chesdachai, Kami D. Kies, John C. O’horo, Daniel C. DeSimone, Parham Sendi, Larry M. Baddour

    (1) Background: Coagulase-negative staphylococci (CoNS) are an important group of organisms that can cause bloodstream infection (BSI) and infective endocarditis (IE). The prevalence of IE in patients with BSI due to different CoNS species, however, has received limited attention; (2) Methods: A retrospective study of adults with monomicrobial CoNS BSI who had undergone echocardiography and a risk factor analysis was done to determine the most common CoNS species that cause definite IE; (3) Results: 247 patients with CoNS BSI were included in the investigation; 49 (19.8%) had definite IE, 124 (50.2%) possible IE, and 74 (30.0%) BSI only. The latter two entities were grouped in one category for further analysis. The most common species in CoNS BSI was Staphylococcus epidermidis (79.4%) and most patients (83.2%) had possible IE/BSI only. 59.1% of patients with BSI due to S. lugdunensis had definite IE. The majority of CoNS were healthcare-associated/nosocomial bacteremia. Multivariable analysis demonstrated that valve disease (p = 0.002) and a foreign cardiovascular material (p < 0.001) were risk factors associated with definite IE. Patients with S. lugdunensis BSI had an 8-fold higher risk of definite IE than did those with S. epidermidis BSI and nearly a 13-fold higher risk than did patients with BSI due to other species of CoNS (p = 0.002); (4) Conclusions: The prevalence of definite IE in patients with BSI due to different CoNS species was significant. CoNS bacteremia, particularly with S. lugdunensis, confers a significant risk of IE, particularly in patients with a valve disease or intravascular foreign body material and should not be immediately dismissed as a contaminant.


  • Open Access

    The Diagnostic Accuracy of Metagenomic Next-Generation Sequencing in DiagnosingPneumocystisPneumonia: A Systemic Review and Meta-analysis

    by Aysun Tekin, Hong Hieu Truong, Lucrezia Rovati, Amos Lal, Danielle J Gerberi, Ognjen Gajic, John C O’horo

    Pneumocystis pneumonia (PCP) is a growing concern as the immunocompromised population expands. Current laboratory approaches are limited. This systematic review aimed to evaluate metagenomic next-generation sequencing (MNGS) tests’ performance in detecting PCP. Five databases were searched through December 19, 2022, to identify original studies comparing MNGS with clinically diagnosed PCP. To assess the accuracy, symmetric hierarchical summary receiver operating characteristic models were used. Eleven observational studies reporting 1442 patients (424 with PCP) were included. Six studies focused exclusively on recipients of biologic immunosuppression (none with HIV-associated immunosuppression). Six were exclusively on bronchoalveolar lavage, while 1 was on blood samples. The sensitivity of MGNS was 0.96 (95% CI, 0.90–0.99), and specificity was 0.96 (95% CI, 0.92–0.98), with negative and positive likelihood ratios of 0.02 (95% CI, 0.01–0.05) and 19.31 (95% CI, 10.26–36.36), respectively. A subgroup analysis of studies exclusively including bronchoalveolar lavage (BAL) and blood samples demonstrated a sensitivity of 0.94 (95% CI, 0.78–0.99) and 0.93 (95% CI, 0.80–0.98) and a specificity of 0.96 (95% CI, 0.88–0.99) and 0.98 (95% CI, 0.76–1.00), respectively. The sensitivity analysis on recipients of biologic immunosuppression showed a sensitivity and specificity of 0.96 (95% CI, 0.90–0.98) and 0.94 (95% CI, 0.84–0.98), respectively. The overall confidence in the estimates was low. Despite the low certainty of evidence, MNGS detects PCP with high sensitivity and specificity. This also applies to recipients of biologic immunosuppression and tests performed exclusively on blood samples without the need for BAL. Further studies are required in individuals with HIV-associated immunosuppression.